stoxline Quote Chart Rank Option Currency Glossary
  
Vaxart, Inc. (VXRT)
0.7462  -0.007 (-0.94%)    02-14 16:00
Open: 0.7501
High: 0.777
Volume: 663,706
  
Pre. Close: 0.7533
Low: 0.7402
Market Cap: 170(M)
Technical analysis
2025-02-14 4:52:24 PM
Short term     
Mid term     
Targets 6-month :  0.9 1-year :  0.99
Resists First :  0.77 Second :  0.85
Pivot price 0.72
Supports First :  0.64 Second :  0.54
MAs MA(5) :  0.72 MA(20) :  0.73
MA(100) :  0.72 MA(250) :  0.81
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  58.3 D(3) :  48
RSI RSI(14): 52.5
52-week High :  1.53 Low :  0.51
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VXRT ] has closed below upper band by 25.8%. Bollinger Bands are 47.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.78 - 0.78 0.78 - 0.78
Low: 0.73 - 0.74 0.74 - 0.74
Close: 0.74 - 0.75 0.75 - 0.75
Company Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Headline News

Sun, 16 Feb 2025
Vaxart (NASDAQ:VXRT) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell? - MarketBeat

Tue, 28 Jan 2025
Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors - GlobeNewswire

Tue, 14 Jan 2025
Vaxart Advances COVID-19 Oral Vaccine to 10,000-Patient Trial, Expands Pipeline with Norovirus Program - StockTitan

Mon, 13 Jan 2025
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - GlobeNewswire

Sat, 04 Jan 2025
Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47% - Simply Wall St

Tue, 19 Nov 2024
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 227 (M)
Shares Float 211 (M)
Held by Insiders 0.8 (%)
Held by Institutions 17.7 (%)
Shares Short 11,270 (K)
Shares Short P.Month 12,070 (K)
Stock Financials
EPS -0.41
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.37
Profit Margin 0 %
Operating Margin -254 %
Return on Assets (ttm) -39.7 %
Return on Equity (ttm) -91.7 %
Qtrly Rev. Growth 371.3 %
Gross Profit (p.s.) -0.23
Sales Per Share 0.06
EBITDA (p.s.) -0.3
Qtrly Earnings Growth 0 %
Operating Cash Flow -62 (M)
Levered Free Cash Flow -32 (M)
Stock Valuations
PE Ratio -1.87
PEG Ratio 0
Price to Book value 1.96
Price to Sales 12.18
Price to Cash Flow -2.75
Stock Dividends
Dividend 12.18
Forward Dividend 0
Dividend Yield 1633.6%
Dividend Pay Date 2024-12-19
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android